DelveInsight’s, “Advanced Melanoma Pipeline Insight 2024” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Advanced Melanoma pipeline landscape. It covers the Advanced Melanoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Melanoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Advanced Melanoma research. Learn more about our innovative pipeline today! @ Advanced Melanoma Pipeline Outlook
Key Takeaways from the Advanced Melanoma Pipeline Report
- In October 2024:- Immunocore Ltd.- A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301). This is a phase 3, randomized, controlled study of IMC-F106C plus nivolumab compared to standard nivolumab regimens in HLA-A*02:01-positive participants with previously untreated advanced melanoma.
- In October 2024:- Replimune Inc.- This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician’s Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease progressed on an anti PD-1 and an anti-CTLA-4 containing regimen (administered either as a combination regimen or in sequence) or who are not candidates for treatment with an anti-CTLA-4 therapy.
- In October 2024:- Biocad- The aim of the study BCD-263-2/UNIVERSE is to demonstrate comparable efficacy and similar safety and immunogenicity profile of BCD-263 and Opdivo after repeated intravenous doses in subjects with advanced unresectable or metastatic melanoma of the skin. During the main study period, subjects will receive therapy with BCD-263 or Opdivo, which will be administered intravenously until disease progression or signs of unacceptable toxicity develop (whichever occurs earlier).
- In October 2024:- Innovent Biologics Co. Ltd- A Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of IBI363 in Subjects With Advanced Melanoma. This is an open-lable, multicenter Phase II study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced melanoma patients
- In October 2024:- Iovance Biotherapeutics Inc.- This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who subsequently have a blinded independent central review- verified confirmed progressive disease (PD) will be offered lifileucel monotherapy in an optional crossover period.
- In October 2024:- Istari Oncology Inc.- This multi-center, open-label, randomized, Phase 2 will investigate the efficacy and safety of lerapolturev alone (Arm 1) or in combination with an anti-PD-1 inhibitor (Arm 2). Following a 6 participant safety run-in period, up to approximately 50 participants with cutaneous melanoma who previously failed anti-PD-1/L1-based therapy will be randomized 1:1 to receive either lerapolturev or lerapolturev plus an anti-PD-1.
- In October 2024:- Regeneron Pharmaceuticals- This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called “study drugs”. The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the combination of fianlimab and cemiplimab is in treating melanoma, in comparison with the combination of two medications, relatlimab and nivolumab, commercialized under the brand name Opdualag™ and approved for the treatment of melanoma in adults and children.
- In October 2024:- Pfizer- This study will compare the efficacy, safety, and tolerability of encorafenib and binimetinib plus pembrolizumab (Triplet Arm) versus placebo plus pembrolizumab (Control Arm) in participants with metastatic or unresectable locally advanced BRAF V600E/K mutation-positive melanoma. The study will have an open-label safety lead-in (SLI) phase to determine the safety recommend Phase 3 dose (RP3D) and pharmacokinetics (PK) of encorafenib and binimetinib plus pembrolizumab combination therapy prior to initiation of the randomized Phase 3 part of the study.
- DelveInsight’s Advanced Melanoma pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Advanced Melanoma treatment.
- The leading Advanced Melanoma Companies such as OncoSec Medical, Immunocore, Sanofi, TILT Biotherapeutics, Novartis Pharmaceuticals, Sumitomo Pharma, BioMed Valley Discoveries, Replimune, ImaginAb, Shanghai Pharmaceuticals, Seagen, Karyopharm Therapeutics, Hoffmann-La Roche, and others.
- Promising Advanced Melanoma Therapies such as Tebentafusp, T3011, IMC-F106C, Relatlimab, HLX208, DCB-BO1301, Pembrolizumab, and others.
Stay informed about the cutting-edge advancements in Advanced Melanoma treatments. Download for updates and be a part of the revolution in cancer care @ Advanced Melanoma Clinical Trials Assessment
Advanced Melanoma Emerging Drugs Profile
- Tebentafusp: Immunocore
Tebentafusp is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. Tebentafusp specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma, and is the first molecule developed using Immunocore’s ImmTAC technology platform designed to redirect and activate T cells to recognize and kill tumor cells. Tebentafusp has been granted Priority Review; Real Time Oncology Review; Breakthrough Therapy designation; Fast Track designation; and orphan drug designation by the FDA in the United States; orphan drug status in the European Union; and Promising Innovative Medicine (PIM) designation under the UK Early Access to Medicines Scheme for metastatic uveal melanoma. The drug is currently being evaluated under Phase II/III clinical trial for the treatment of Advanced Melanoma.
- TAVO: OncoSec Medical
TAVO is DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. TAVO is administered directly into the tumor using OncoSec’s proprietary EP gene delivery system, which employs a series of momentary energy pulses. Those pulses are designed to increase the permeability of the cell membrane and facilitate uptake of IL-12 coded DNA into the tumor cells. The drug is currently being evaluated under Phase II clinical trials for the treatment of Advanced Melanoma.
Learn more about Advanced Melanoma Drugs opportunities in our groundbreaking metastatic prostate cancer research and development projects @ Advanced Melanoma Unmet Needs
Advanced Melanoma Companies
OncoSec Medical, Immunocore, Sanofi, TILT Biotherapeutics, Novartis Pharmaceuticals, Sumitomo Pharma, BioMed Valley Discoveries, Replimune, ImaginAb, Shanghai Pharmaceuticals, Seagen, Karyopharm Therapeutics, Hoffmann-La Roche, and others.
Advanced Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
Advanced Melanoma Products have been categorized under various Molecule types such as
- Monoclonal antibody
- Small molecule
- Peptide
Discover the latest advancements in Advanced Melanoma treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Advanced Melanoma Market Drivers and Barriers, and Future Perspectives
Scope of the Advanced Melanoma Pipeline Report
- Coverage- Global
- Advanced Melanoma Companies- OncoSec Medical, Immunocore, Sanofi, TILT Biotherapeutics, Novartis Pharmaceuticals, Sumitomo Pharma, BioMed Valley Discoveries, Replimune, ImaginAb, Shanghai Pharmaceuticals, Seagen, Karyopharm Therapeutics, Hoffmann-La Roche, and others.
- Advanced Melanoma Therapies- Tebentafusp, T3011, IMC-F106C, Relatlimab, HLX208, DCB-BO1301, Pembrolizumab, and others.
- Advanced Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Advanced Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Advanced Melanoma Pipeline on our website @ Advanced Melanoma Emerging Drugs and Companies
Table of Content
- Introduction
- Executive Summary
- Advanced Melanoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Advanced Melanoma– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- TAVO: OncoSec Medical
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Advanced Melanoma Key Companies
- Advanced Melanoma Key Products
- Advanced Melanoma- Unmet Needs
- Advanced Melanoma- Market Drivers and Barriers
- Advanced Melanoma- Future Perspectives and Conclusion
- Advanced Melanoma Analyst Views
- Advanced Melanoma Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/